Optimizing Antiplatelet Therapy in Cardiogenic Shock-Optimal Antiplatelet Strategies on High-Risk Patients, Dr. Srihari Naidu

Optimal Antiplatelet Strategies on High-Risk Patients, Dr. Srihari Naidu

Video Transcription

Video Summary

The speaker discusses the evolving use of intravenous antiplatelet agents, focusing on glycoprotein IIb/IIIa inhibitors (GPI) and IV P2Y12 inhibitors like cangrelor. Current guidelines recommend limited GPI use, mainly as bailout for large thrombus or PCI complications, due to bleeding risks. Cangrelor offers rapid platelet inhibition, benefiting high-risk groups such as STEMI, shock, and complex PCI patients by reducing ischemic events, especially in the crucial first hours. Routine preloading with oral agents is downgraded. For cardiac arrest, benefits are unclear. The speaker advocates a modern algorithm: no preloading except STEMI, use cangrelor for high risk/shock, loading oral agents after intervention, and minimal GPI use.

Keywords

intravenous antiplatelet agents

glycoprotein IIb/IIIa inhibitors

cangrelor

STEMI treatment

percutaneous coronary intervention